Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 8931-230
Fax: +49 (0)711 - 8931-323
send an Email


Thrombotic risk factors in Chinese Budd-Chiari syndrome patients

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Theme Issue
High on-treatment platelet reactivity

Issue: 2013: 109/5(May) pp. 769-975
Pages: 878-884

Thrombotic risk factors in Chinese Budd-Chiari syndrome patients

An observational study with a systematic review of the literature

Online Supplementary Material

X. Qi (1), F. Wu (1), W. Ren (1), C. He (1), Z. Yin (1), J. Niu (1), M. Bai (1), Z. Yang (1), K. Wu (1, 2), D. Fan (1, 2), G. Han (1)

(1) Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China; (2) State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi’an, China


factor V Leiden mutation, Budd-Chiari syndrome, myeloproliferative neoplasm, prothrombin G20210A mutation, paroxysmal nocturnal haemoglobinuria


In Western countries, thrombotic risk factors for Budd-Chiari syndrome (BCS) are very common, including factor V Leiden mutation, prothrombin G20210A mutation, myeloproliferative neoplasms, paroxysmal nocturnal haemoglobinuria, etc. However, the data regarding thrombotic risk factors in Chinese BCS patients are extremely limited. An observational study was conducted to examine this issue. A total of 246 BCS patients who were consecutively admitted to our department between July 1999 and December 2011 were invited to be examined for thrombotic risk factors. Of these, 169 patients were enrolled. Neither factor V Leiden mutation nor prothrombin G20210A mutation was found in any of 136 patients tested. JAK2 V617F mutation was positive in four of 169 patients tested. Neither MPL W515L/K mutation nor JAK2 exon 12 mutation was found in any of 135 patients tested. Overt myeloproliferative neoplasms were diagnosed in five patients (polycythemia vera, n=3; essential thrombocythemia, n=1; idiopathic myelofibrosis, n=1). Two of them had positive JAK2 V617F mutation. Both CD55 and CD59 deficiencies were found in one of 166 patients tested. This patient had a previous history of paroxysmal nocturnal haemo-globinuria before BCS. Anticardiolipin IgG antibodies were positive or weakly positive in six of 166 patients tested. Hyperhomocysteinaemia was found in 64 of 128 patients tested. 5,10-methylenetetrahydrofolate reductase C677T mutation was found in 96 of 135 patients tested. In conclusion, factor V Leiden mutation, prothrombin G20210A mutation, myeloproliferative neoplasms, and paroxysmal nocturnal haemoglobinuria are very rare in Chinese BCS patients, suggesting that the etiological distribution of BCS might be different between Western countries and China.

You may also be interested in...

Emile L. E. de Bruijne 1, Sarwa Darwish Murad 2, Moniek P. M. de Maat 1, Michael W. T. Tanck 3, Elizabeth B. Haagsma 4, Bart van Hoek 5, Frits R. Rosendaal 6, Harry L. A. Janssen 2, Frank W. G. Leebeek 1, for the Liver and Thrombosis Study Group

Thromb Haemost 2007 97 2: 181-185

Christine Biron-Andreani 1, Jean-Francois Schved 1, Jean-Pierre Daures 2

Thromb Haemost 2006 96 1: 14-18

Walid Zammiti 1 , Nabil Mtiraoui 1 , Eric Mercier 2 , Nesrine Abboud 1 , Sarra Saidi 1 , Touhami Mahjoub1 , Wassim Y. Almawi 3 , Jean-Christophe Gris 2

Thromb Haemost 2006 95 4: 612-617